ArticleJAMA network open2023

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands.

Marianne Luyendijk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.